<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02450123</url>
  </required_header>
  <id_info>
    <org_study_id>2014-10-076</org_study_id>
    <nct_id>NCT02450123</nct_id>
  </id_info>
  <brief_title>Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study of sunitinib in patients with RET fusion positive or FGFR2&#xD;
      Amplification Refractory solid tumors.&#xD;
&#xD;
      This study is a single-arm, pilot study of sunitinib in subjects with Refractory solid tumors&#xD;
      harboring RET fusion positive or FGFR2 Amplification sunitinib 50mg will be administered&#xD;
      orally once a day 42 days.Study treatment will be continued until objective disease&#xD;
      progression.&#xD;
&#xD;
      To investigate the efficacy of sunitinib in subjects with Refractory solid tumors harboring&#xD;
      RET fusion positive or FGFR2 Amplification.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>expected average of 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>expected average of 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>expected average of 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>expected average of 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events as a measure of toxicity profile</measure>
    <time_frame>expected average of 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">3</enrollment>
  <condition>Refractory Solid Tumors</condition>
  <arm_group>
    <arm_group_label>sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sunitinib 50mg will be administered orally once a day 42 days.Study treatment will be continued until objective disease progression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib</intervention_name>
    <arm_group_label>sunitinib</arm_group_label>
    <other_name>sutene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of fully informed consent prior to any study specific procedures.&#xD;
&#xD;
          2. Patients must be ≥20 years of age.&#xD;
&#xD;
          3. RET fusion positive,FGFR amplification, Refractory Solid Tumors that has recurred or&#xD;
             progressed following standard therapy, or that has not responded to standard therapy,&#xD;
             or for which there is no standard therapy.&#xD;
&#xD;
          4. ECOG performance status 0-2.&#xD;
&#xD;
          5. Have measurable or evaluated disease based on RECIST1.1. as determined by&#xD;
             investigator.&#xD;
&#xD;
          6. Adequate Organ Function Laboratory Values&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 x 109/L, Hemoglobin ≥ 9g/dL, Platelets ≥ 75 x&#xD;
                  109/L&#xD;
&#xD;
               -  bilirubin ≤ 1.5 x upper limit of normal AST/ALT ≤ 2.5 x upper limit of normal&#xD;
                  (5.0 X upper limit of normal , for subjects with liver metastases)&#xD;
&#xD;
               -  creatinine ≤1.5 x UNL&#xD;
&#xD;
          7. Patients of child-bearing potential should be using adequate contraceptive measures&#xD;
             (two forms of highly reliable methods) should not be breast feeding and must have a&#xD;
             negative pregnancy test prior to start of dosing.&#xD;
&#xD;
          8. Adequate heart function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with second primary cancer, except: adequately treated non-melanoma skin&#xD;
             cancer, curatively treated in-situ cancer of the cervix, or other solid tumours&#xD;
             curatively treated with no evidence of disease for ≤5 years.&#xD;
&#xD;
          2. Has known active central nervous system (CNS) metastases.&#xD;
&#xD;
          3. Has an active infection requiring systemic therapy.&#xD;
&#xD;
          4. Pregnancy or breast feeding&#xD;
&#xD;
          5. Patients with cardiac problem.&#xD;
&#xD;
          6. Any previous treatment with sunitinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joon Oh Park, MD,Ph.D.</last_name>
    <phone>2-3410-3459</phone>
    <phone_ext>82</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joon Oh Park, M.D., Ph.D</last_name>
      <phone>82 2 3410 3459</phone>
      <email>oncopark@skku.edu</email>
    </contact>
    <contact_backup>
      <last_name>yoon Jeong Ahn</last_name>
      <phone>221487395</phone>
      <phone_ext>82</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Joon Oh Park</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

